Application of An Improved HPLC-FL Method to Screen Serine Palmitoyl Transferase Inhibitors by S. Bertini et al.
molecules
Communication
Application of An Improved HPLC-FL Method to
Screen Serine Palmitoyl Transferase Inhibitors
Simone Bertini 1,*, Giuseppe Saccomanni 1, Sara Del Carlo 1 ID , Maria Digiacomo 1,
Claudia Gargini 1, Ilaria Piano 1, Giuseppe Matteo Campisi 2, Riccardo Ghidoni 2,
Marco Macchia 1 and Clementina Manera 1
1 Dipartimento di Farmacia, Università di Pisa, Via Bonanno 6, 56126-Pisa, Italy;
giuseppe.saccomanni@unipi.it (G.S); delcarlosara@gmail.com (S.D.C.); maria.digiacomo@unipi.it (M.D.);
maria.gargini@unipi.it (C.G.); ilaria.piano@unipi.it (I.P.); marco.macchia@unipi.it (M.M);
clementina.manera@unipi.it (C.M.)
2 Laboratorio di Biochimica e Biologia Molecolare, Dipartimento di Scienze della Salute, Via A. di Rudinì 8,
20142 Milano, Italy; giuseppe.campisi@unimi.it (G.M.C.); riccardo.ghidoni@unimi.it (R.G.)
* Correspondence: simone.bertini@unipi.it; Tel.: +39-050-221-9579
Received: 5 July 2017; Accepted: 14 July 2017; Published: 17 July 2017
Abstract: In this work, we reported the application and validation of an improved high-performance
liquid chromatography method coupled with a fluorimetric detector (HPLC-FL) to screen the activity
of two heterocyclic derivatives reported as serine palmitoyl transferase (SPT) inhibitors. The analytical
conditions were optimized in terms of the derivatization procedure, chromatographic condition,
extraction procedure, and method validation according to EMEA guidelines. Once fully optimized,
the method was applied to assess the SPT-inhibitory activity of the above-mentioned derivatives and
of the reference inhibitor myriocin. The obtained results, expressed as a percentage of residual SPT
activity, were compared to those obtained with the reference radio immune assay (RIA). The good
correlation between the two types of assay demonstrated that the improved HPLC-FL method is
suitable for a preliminary and rapid screening of potential SPT-inhibitors.
Keywords: HPLC; serine palmitoyl transferase; SPT; screening; enzymatic assay
1. Introduction
Serine palmitoyl transferase (SPT) is a pyridoxal-5’-phosphate (PLP) dependent enzyme that
plays a crucial role in the biosynthesis of sphingolipids [1]. It catalyzes a Claisen-like condensation
between L-serine and palmitoyl-CoA, producing 3-keto-dihydrosphingosine (3-KDS) [2,3]. This
reaction represents the first and rate-limiting step of the de novo biosynthetic pathway of ceramide,
a sphingolipid bioactive molecule involved in fundamental cell functions, such as proliferation,
differentiation, and apoptosis [4,5].
Recent studies highlight a close correlation between SPT, intracellular levels of ceramide and
the onset/progression of several diseases, including neurodegenerative disorders. Mutations of the
gene encoding for the first SPT subunit have been recognized as the cause of the hereditary sensory
neuropathy type 1 [6,7]. In brain tissue of Alzheimer’s disease patients, high levels of ceramide and
of SPT have been detected [8]. It has also been demonstrated that inhibition of the latter causes a
reduction of β-amyloid (main constituent of senile plaques), while the administration of ceramide
produces an opposite effect [9]. Intraocular administration of myriocin, a potent SPT-inhibitor, in
RD10 mutant mice, a validated model of human retinitis pigmentosa, has been shown to preserve
the structure and function of photoreceptors [10,11]. An enhanced ceramide synthesis, shown to be
involved in ischemia/reperfusion injury and myriocin treatment, could be proposed as a strategy for
myocardial pharmacological postconditioning [12]. Moreover, de novo synthesized ceramide has been
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shown to mediate the inflammatory response induced by Aspergillus fumigatus infection in mice airway
epithelia, and intratracheal administration of myriocin reduced inflammation and exerted antifungal
activity [13]. Finally, the anti-inflammatory action of myriocin was highlighted in a mice model of
cystic fibrosis [14].
Therefore, pharmacological interventions aimed at inhibiting SPT and, as a consequence, lowering
intracellular levels of ceramide, may represent a new strategy for the treatment of these diseases.
Among the currently known SPT-inhibitors, the above-mentioned natural product myriocin is the
most potent and selective one. It is a widely used chemical probe in research about SPT and, more
in general, sphingolipids [15]. Unfortunately, the lipophilic structure of this molecule has a negative
impact on its pharmacokinetic profile and therefore limits its use as a therapeutic agent.
For the above reasons, there is a growing interest towards the discovery of new molecules
as SPT-inhibitors. In the meantime, a method aimed at rapidly assessing their activities would
be desirable.
At present, there is a reference radiometric inhibition assay (RIA) that involves the use of a
radioactive substrate: after incubation of a cell lysate with [3H]L-serine, palmitoyl-CoA and cofactor
(PLP), a liquid–liquid extraction of the tritiated product ([3H]-KDS) is performed and it is quantified
using a scintillation counter [16].
A few years ago, a radioactive-free method that allows quantification of 3-KDS as the direct
product of SPT reaction using a high-performance liquid chromatograph equipped with a fluorimetric
detector (HPLC-FL) was reported [17]. This method uses HEK 293 cell lysate an as enzyme source and
involves the reduction of 3-KDS with NaBH4 leading to sphinganine (erythro- and threo-sphinganine)
which is derivatized with ortho-phthalaldehyde (OPA) and 2-mercaptoethanol. The isoindole derivative
thus formed is quantified using a HPLC apparatus coupled with a fluorimetric detector.
Although such a method has led to significant improvements in terms of safety, sensitivity, and
reproducibility, its application to assess the activity of SPT-inhibitors has not been reported to date.
In the present work, we describe the application of the above-mentioned HPLC-FL method, with
the aim of screening the activity of some heterocyclic compounds reported as SPT-inhibitors [18].
In particular, we focused our attention on two 1,3-dihydro-2H-benzimidazol-2-oxo-derivatives
(compounds 1 and 2) that are described in Figure 1. For this purpose, we prepared such derivatives
in our research laboratories following a different synthetic route with respect to that reported [18].
The selected compounds were tested using both the HPLC-FL assay and the reference RIA, and the
results obtained were compared, highlighting a good correlation between the two methods.
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2. Results and Discussion
2.1. Synthesis
The synthesis of compound 1 and 2 is shown in Scheme 1. A variation of the synthetic
approach used in the Pfizer patent to obtain the titled compounds was performed [18]. Commercial
3-chloro-4-nitrobenzonitrile 3 and commercial 4-amino-1-BOC-piperidine 4 were reacted in the
presence of N,N-diisopropylethylamine (DIPEA) for three days at room temperature (RT), leading to
intermediate 5 in good yields. To reduce the reaction time, this step was also performed using
a microwave reactor, which allowed us to obtain comparable amounts of 5 after 15 min. The
nitro-derivative 5 was then reduced using Pd/C at RT, leading the aniline derivative 6 which was
cyclized in the presence of 1,1’-carbonyldiimidazole (CDI) and 4-dimethylaminopyridine (DMAP)
for two days. As well as for the first step, this reaction was also performed using a microwave
reactor, obtaining comparable yield of 7 (85%) after 15 min. Then the piperidine portion linked to the
2-oxo-benzimidazole derivative 7 was deprotected from the carbamate function in acidic conditions,
obtaining a quantitative amount of 8, which was reacted with 2-bromo-4’-chloroacetophenone in
presence of triethylammine (TEA) leading to compound 2. For the synthesis of compound 1,
the tetrazolic portion was formed before the functionalization with the p-chloro-phenacyl group.
A solventless reaction procedure was performed [19]: 7 was heated at 125 ◦C for 24 h under
nitrogen atmosphere in the presence of trimethylsilyl azide (TMSN3) and tetrabutylammonium
fluoride (TBAF). Treatment of the crude reaction mixture with ice and 10% HCl led to 9 as pure
precipitate, whose BOC-protective group was removed by acidic hydrolysis. Then, 10 was reacted
with 2-bromo-4’-chloroacetophenone in the presence of triethylamine (TEA) at 0 ◦C. Isolation of the
desired product was performed using a selective liquid extraction and purity of 1 was assessed by
HPLC. The structure of the compound was confirmed by LC-MS analysis.
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2.2. Optimization of Analytical Procedure
2.2.1. Derivatization Conditions
In order to optimize the derivatization conditions (generally performed at RT), we decided to
gently warm (40 ◦C) the samples during this procedure: different concentration of sphinganine were
added to the “derivatization solution” (990 µL of borate buffer (pH 10.5), 5 µL of OPA and 0.5 µL of
2-mercaptoethanol) and allowed to react for different times (5 and 30 min, 1, 1.5, 2, 2.5 h). To evaluate
the formed isoindole derivatives, the chromatographic condition previously reported was applied [17],
and on the basis of the chromatographic resolution, the reaction time needed to obtain a quantitative
conversion of sphinganine to the isoindole derivatives was set. The area values corresponding to a
1.5 h of reaction at 40 ◦C had a standard deviation lower than 15%, suggesting that the reaction was
completed (Figure 2).
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2.2.3. Extraction Procedure
HEK 293 cell lysate represents a complex matrix, therefore a selective extraction procedure was
needed in order to obtain a good resolution of the analytes. Cell lysate pellet (2 mg/mL) was spiked
with sphinganine or 3-KDS: to 200 µL of this sample was added NaBH4 to reduce 3-KDS to sphinganine.
The use of sphinganine-spiked sample allowed us to evaluate the complete reduction of 3-KDS. Then,
100 µL of NH4OH (2 M) was added and a liquid–liquid extraction procedure was performed: the best
organic mixture to be used was selected by testing a different mixture of MeOH and CHCl3 (a mixture
generally used in sphingolipids analysis). At the same time, washing of the organic phase by addition
of alkaline water was tested to remove interfering lipids [20]. The data obtained highlighted that
the use of alkaline solution to remove contaminates from the organic phase was necessary, and a
MeOH–CHCl3 (2:1, v/v) mixture allowed quantitative yields to be obtained. Then, a defined volume
of organic phase (150 µL of lower phase) was concentrated under N2 and the residue reconstituted
with 145 µL of MeOH–EtOH–H2O (85:47.5:17.5, v/v/v). Then, the “derivatization solution” (5 µL)
was added. Once optimized, the extraction procedure, incubation experiments of both pellet and
supernatant fractions of HEK293 cell lysate (obtained after ultracentrifugation at 33,000 rpm, 40 min,
4 ◦C) with substrates and cofactor were performed. The data confirmed the presence of SPT activity in
the pellet fraction whereas no enzyme activity was detected in the supernatant portion.
2.2.4. Method Validation
The method was validated according to EMEA guidelines [21]. A calibration curve was developed
by analyzing blank samples spiked with sphinganine standard solutions, obtaining a linearity range
from 10 nM to 3.2 µM and a correlation coefficient (R2) of 0.998 (Figure 4). Recovery of sphinganine
was 97 ± 2% and lower limit of quantification (LLOQ) and detection (LLOD) were estimated to
correspond to 10 and 5 nM, respectively. Specificity with regard to other co-eluting components was
investigated by comparing the chromatograms of different batches of blank matrices to those from
spiked cell lysate solutions and test samples. The chromatographic condition developed avoid the
presence of an interference peak. Typical retention times for sphinganine were 16.6 ± 0.1 (threo) and
17.6 ± 0.2 min (erythro).
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Low-, medium-, and high-quality control sa l ere used to evaluate the accuracy and
precision of the method. The data obtained were shown to be in agreement with that recommended by
EMEA guidelines (Table 1) [21].
Table 1. Accuracy and precision evaluation ( S ) of quality control (QC) samples.
QC Sample Accuracy Precision
Within-Run Between-Run
LOW (100 nM) 9.92% 9.1% 13.3%
MEDIUM (800 nM) 5.73% 14.8% 11.0%
HIGH (1600 nM) 8.57% 6.3% 7.4%
Molecules 2017, 22, 1198 6 of 13
2.2.5. Incubation Period Evaluation
To 2 mg/mL of cell lysate (180 µL), 10 µL of the solvent used for the control sample and 10 µL of
“mix” solution containing L-serine, palmitoyl-CoA, and PLP (100 mM L-serine, 1.0 mM palmitoyl-CoA,
0.4 mM PLP) were added. Enzyme initial velocity was evaluated by incubating control samples at
37 ◦C for different times (5 and 30 min, 1, 1.5, 2 h) to choose the suitable incubation period. These
experiments were performed by testing triplicates. Evaluation of sphinganine concentration (and
therefore of the produced 3-KDS) showed a linearity of enzyme activity from 5 min to 1.5 h (Figure 5).
Therefore, the selected incubation period was 1 h.
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2.2.6. Scree ing of SPT Inhibitors
Once chromatographic and assay conditions w re optimized, myriocin was tested for its inhibitory
activity towards SPT.
Evaluation of dos –response inhibiti n of myriocin using the HPLC-FL ass y was performed
by testi g concentratio s ranging from 2.5 pM to 25 nM. The data ighlighted the strong inhibitory
activity of this molecule and an IC50 value of 160.0 ± 1.2 pM (Figure 6).
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Table 2. Screening of compounds 1 and 2 (at a concentration of 50 µM) on human SPT by RIA and
HPLC-FL assay. 1
Compound % of Residual SPT Activity
RIA HPLC-FL
1 1.8 ± 0.8 1.3 ± 0.5
2 5.7 ± 2.1 4.1 ± 1.5
1 Data are obtained from three experiments and values are expressed as average ± SD.
3. Materials and Methods
3.1. Chemical Synthesis
Reagents were purchased from commercial sources and used without further purification. Melting
points were determined on a Kofler hot stage apparatus and were uncorrected. 1H-NMR and 13C-NMR
spectra were recorded with a Varian Gemini 200 spectrometer (operating at 200 MHz). Chemical
shifts (δ) are reported in parts per million related to the residual solvent signal, while coupling
constants (J) are expressed in Hertz (Hz). Microwave-assisted reactions were run in a Biotage®
microwave synthesizer (Uppsala, Sweden). Merck silica gel 60 was used for flash chromatography
(230−400 mesh). The chemical purity of the target compounds was determined under the following
conditions: the HPLC system was an LC Workstation Prostar (Varian, Inc., Walnut Creek, CA, USA)
consisting of a high-pressure mixer pump (ProStar, model 230), UV-DAD detector (ProStar, model
330) with wavelengths set at 220 and 320 nm, and a loop of 20 µL. Data were processed by a Star
LC Workstation (Varian, Inc.). Chromatographic separation was performed on a Luna C18 ODS2
analytical column (150 × 4.6 mm inner diameter, 3 µm particle size, Phenomenex, Torrance, CA, USA)
maintained at 25 ◦C. The mobile phase consisted of acetonitrile:water. The purity of each compound
was >96% in either analysis. For the final products 1 and 2, LC-MS analysis was accomplished using a
PerkinElmer (Waltham, MA, USA) 200 Series micro-pump system, equipped with autosampler and
column oven, both 200 Series from Perkin Elmer and an Applied Biosystems/Sciex (Foster City, CA,
USA) API 4000 triple quadrupole mass spectrometer, equipped with a Turbo V electrospray ionization
source (ESI).
3.1.1. tert-Butyl 4-(2-nitro-4-cyanophenylamino)-piperidine-1-carboxylate (5)
In a microwave vial, DIPEA (3.5 mL, 20.0 mmol) and 4-chloro-3-nitrobenzonitrile 3 (1.83 g,
10.0 mmol) were mixed in 4 mL of dimethylformamide (DMF). Afterwards, 4-amino-1-BOC-piperidine
4 (2.40 g, 12.0 mmol) were added and the vial was capped. Reaction conditions: 15 min; 130 ◦C; 5 bar.
After cooling, 50 mL of ethyl acetate and 10 mL of tetrahydrofuran (THF) were added to the reaction
mixture. The organic layer was washed with 0.5 M solution of hydrochloric acid (2 × 40 mL) and brine
in a separating funnel. The organic layer was dried over magnesium sulfate, filtrated and evaporated
in vacuo, leading to the desired compound as a yellow powder (3.11 g, 9.0 mmol). Yield: 90%. The
titled compound was crystallized from toluene. 1H-NMR (CDCl3, 200 MHz): 8.54 (d, 1H, J = 1.9 Hz),
8.45 (bs, 1H), 7.61 (dd, 1H, J = 8.8 Hz, J = 1.8 Hz), 6.96 (d, 1H, J = 8.8 Hz), 4.11–3.88 (m, 2H), 3.74-3.65
(m, 1H), 3.11–2.98 (m, 2H), 2.19-1.98 (m, 2H), 1.96–1.58 (m, 2H), 1.48 (s, 9H).
3.1.2. tert-Butyl 4-(2-amino-4-cyanophenylamino)-1-piperidinecarboxylate (6)
tert-butyl 4-(2-nitro-4-cyanophenylamino)-1-piperidinecarboxylate (5) (1.21 g, 3.5 mmol) was
dissolved in 120 mL of a solution of THF–absolute EtOH (5:95, v/v). To the obtained solution, Pd/C
was added, and the mixture was placed under hydrogen and stirred at RT for 4 h. Afterwards, the
solution was filtered on a silica pad and washed with ethyl acetate (100 mL). The organic phase
was concentrated in vacuo, leading to a white powder (0.996 g, 3.15 mmol). Yield: 90%. The titled
compound was crystallized from isopropanol. 1H-NMR (CDCl3, 200 MHz): 7.15 (d, 1H, J = 8.2 Hz),
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6.96 (s, 1H), 6.60 (d, 1H, J = 8.2 Hz), 4.11–3.92 (m, 3H), 3.57-3.39 (m, 3H), 3.02–2.86 (m, 2H), 2.08–2.01
(m, 2H), 1.47 (s, 11H). 13C-NMR (CDCl3): 154.91, 141.22, 133.34, 126.78, 120.70, 120.10, 110.51, 99.49,
80.04, 49.93, 42.77, 32.36, 28.73.
3.1.3. tert-Butyl 4-(6-cyano-2-oxobenzimidazol-3-yl)piperidine-1-carboxylate (7)
Method A: to a solution of 6 (0.65 g, 2.0 mmol) in 25 mL of anhydrous THF, CDI (0.68 g,
4.2 mmol), and DMAP (0.24 g, 2.0 mmol) were added and the resulting mixture was heated at
100 ◦C for 5 h. The solution was cooled to RT and allowed to sit for two days. Then, it was diluted
with 80 mL of AcOEt and washed with aqueous hydrogen chloride (0.6 M, 3 × 60 mL) and brine
(2 × 60 mL), dried with magnesium sulfate, filtered, and concentrated. The crude product was purified
by flash chromatography (AcOEt:n-hexane 3:1), dissolving the mixture in CHCl3 (10 mL), or by
crystallization (toluene) (0.623 g,1.82 mmol). Yield: 91%. Method B: compound 6 (0.65 g, 2.0 mmol),
N,N’-carbonyldiimidazole (0.68 g, 4.2 mmol), DMAP (0.24 mg, 2.0 mmol), and anhydrous THF (10 mL)
were mixed in a microwave vial (1–20 mL). The mixture was heated at 120 ◦C, for 15 min (7 bar; cooling
on; stirring on). The mixture obtained was diluted with 80 mL of AcOEt and washed with aqueous
hydrogen chloride (0.6 M, 3 × 60 mL) and brine (2 × 60 mL), dried with magnesium sulfate, filtered,
and concentrated. The crude product was purified by flash chromatography (AcOEt:n-hexane 3:1),
dissolving the mixture in CHCl3 (10 mL), or by crystallization (toluene) (0.582 g, 1.70 mmol). Yield:
85%. 1H-NMR (DMSO, 200 MHz): δ 11.36 (bs, 1H), 7.49–7.36 (m, 3H), 4.48–4.23 (m, 1H), 4.23–4.05
(m, 2H), 2.89–2.73 (m, 2H), 2.32–2.16 (m, 2H), 1.74–1.65 (m, 2H), 1.43 (s, 9H). 13C-NMR (DMSO):
δ 153.13, 153.00, 132.46, 127.91, 125.02, 119.01, 110.99, 101.80, 108.47, 78.22, 49.91, 42.44, 27.84, 27.55.
3.1.4. 2,3-Dihydro-2-oxo-1-(piperidin-4-yl)-benzimidazole-5-carbonitrile (8)
CF3COOH (1.15 mL, 15.0 mmol) was added to a suspension of 7 (0.51 g, 1.5 mmol) in 5 mL of
CH2Cl2. The obtained solution was stirred at RT for 2 h, then concentrated in vacuo and a saturated
solution of NaHCO3 was added to reach pH 6–7. Then, the mixture was put in an ice bath for 1 h. The
obtained precipitate was filtered and dried at 50 ◦C in vacuo (0.290 g, 1.2 mmol). Yield: 80%. 1H-NMR
(DMSO, 200 MHz): δ 11.50 (bs, 1H), 9.25 (br, 1H), 7.69 (d, 1H, J = 8.0 Hz), 7.53–7.41 (m, 2H), 4.63–4.56
(m, 1H), 3.47–3.01 (m, 4H), 2.68–2.52 (m, 2H), 1.97–185 (m, 2H). 13C-NMR (DMSO): δ 152.88, 132.08,
128.06, 124.98, 118.93, 111.27, 108.38, 102.1, 46.79, 42.42, 24.64.
3.1.5. {1-[2-(4-Chlorophenyl)-2-oxoethyl]piperidin-4-yl}-2,3-dihydro-2-oxo-benzimidazole-5-
carbonitrile (2)
Et3N (167 µL, 1.2 mmol) and 2-bromo-p-chloroacetophenone (1.2 mmol) were added to a solution
of 8 (0.24 g, 1.0 mmol) in 6 mL of THF–anhydrous DMF (1:1, v/v), and the resulting mixture was
stirred at RT for 2 h. The reaction mixture was then concentrated, treated with ice/water, and extracted
with CHCl3. The organic layer was dried with magnesium sulfate, filtered, and concentrated in vacuo.
The crude mixture was purified by crystallization or flash chromatography (0.276 g, 0.70 mmol). Yield:
70%. 1H-NMR (DMSO, 200 MHz): δ 11.44 (bs, 1H), 8.02–.19 (m, 7H), 5.05 (s, 2H), 4.66–4.55 (m, 1H),
3.73–3.60 (m, 2H), 2.87–2.63 (m, 2H), 2.05–1.81 (m, 4H). 13C-NMR (DMSO): δ 190.06, 152.88, 139.04,
131.92, 129.48, 128.57, 128.03, 125.4, 118.94, 111.27, 108.70, 102.15, 60.74, 52.24, 47.99, 46.30, 24.82.
3.1.6. tert-Butyl-4-[2-oxo-5-(tetrazol-5-yl)-2,3-dihydro-benzimidazol-1-yl]piperidine-1-carboxylate (9)
In a screw capped vial equipped with a magnetic stir bar, TBAF (1 M in THF, 0.5 mL, 0.5 mmol),
tert-butyl 4-(6-cyano-2-oxobenzimidazol-3-yl)piperidine-1-carboxylate (7) (0.34 g, 1.0 mmol), and
TMSN3 (0.26 mL, 2.0 mmol) were added under nitrogen. The resulting mixture was heated under
vigorous stirring at 125 ◦C for 48 h. After cooling, the crude reaction mixture was treated with ice and
10% HCl aqueous solution, obtaining a suspension. The solid was filtered and dried at 50 ◦C in vacuo
(0.289 g, 0.75 mmol). Yield: 75%. 1H-NMR (DMSO, 200 MHz): δ 11.22 (bs, 1H), 7.75–7.36 (m, 3H),
4.32 (m, 1H), 4.08–4.04 (m, 2H), 2.92–2.73 (m, 2H), 2.19–2.12 (m, 2H), 1.72–1.59 (m, 2H), 1.38 (s, 9H).
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13C-NMR (DMSO): δ 153, 10, 131.00, 128.24, 119.21, 115.57, 108.39, 106.34, 78.21, 55.32, 49.67, 42.41,
27.88, 27.51.
3.1.7. 1-(Piperidin-4-yl)-5-(tetrazol-5-yl)-1H-benzimidazol-2-one (10)
CF3COOH (0.54 mL, 7.0 mmol) was added to a suspension of 9 (0.270 g, 0.7 mmol) in 5 mL of
CH2Cl2. The obtained solution was stirred at RT for 2 h and concentrated in vacuo. Ice and a saturated
solution of NaHCO3 were added to reach pH 6–7. The resulting precipitate was filtered and dried
at 50 ◦C in vacuo (0.140 g, 0.49 mmol). Yield: 70%. 1H-NMR (DMSO, 200 MHz): δ 10.92 (bs, 1H),
7.80–7.25 (m, 3H), 4.56–4.48 (m, 1H), 3.27–1.65 (m, 9H). 13C-NMR (CD3OD): δ 165.73, 156.21, 132.10,
122.56, 122.088, 121.03, 110.71, 108.56, 52.08, 46.61, 29.57.
3.1.8. {1-[2-(4-Chlorophenyl)-2-oxoethyl]piperidin-4-yl}-5-(2H-tetrazol-5-yl)-2,3-dihydro-
benzimidazol-2-one (1)
Et3N (0.07 mL, 0.5 mmol) was added to an ice bath-cooled solution of 10 (0.143 g, 0.5 mmol) in
3 mL of anhydrous DMF. A solution of 2-bromo-p-chloroacetophenone (0.117 g, 0.5 mmol) in DMF
(0.5 mL) was added dropwise. The reaction was stirred at 0 ◦C for 1.5 h. Then, ice was added to the
reaction mixture and the formed precipitate was filtered and triturated with diethyl ether, obtaining a
white residue (0.123 g, 0.28 mmol). Yield: 56%. The white residue was treated with a small amount
of MeOH and each organic fraction was analyzed with a HPLC system coupled to a detector UV set
at 254 nm, to assess fraction purity. The organic fractions were collected and dried under nitrogen.
Chromatographic separation was performed on a Luna C18 ODS2 analytical columns (150 × 4.6 mm
inner diameter, 3 µ particle size, Phenomenex) maintained at 25 ◦C. The mobile phase consisted of
acetonitrile-buffer (10 mM AcONH4, adjusted to pH 7.0 with NH4OH; 50:50, v/v) at a flow rate of
0.5 mL/min. 1H-NMR (DMSO, 200 MHz): δ 11.11 (bs, 1H), 8.07–7.34 (m, 7H), 6.65 (s, 2H), 4.43–3.95
(m, 2H), 3.83 (s, 1H), 3.23–3.01 (m, 2H), 2.45–1.18 (m, 4H). 13C-NMR (DMSO): δ 191.66, 155.88, 132.60,
132.01, 130.57, 129.74, 128.57, 128.90, 128.6, 126.2, 109.97, 108.66, 60.74, 53.24, 48.92, 36.30.
3.2. Radiometric Inhibition Assay (RIA)
3.2.1. Materials
Pyridoxal-5’-phosphate, L-Serine, and palmitoyl coenzyme A were purchased from Sigma-Aldrich
(St. Louis, MI, USA). Sphingosine-1-phosphate (S1P) was purchased from Avanti Polar Lipids. DMEM
culture media and fetal bovine serum (FBS) were purchased from EuroClone Life Science Division
(Milan, Italy). L-[3H(G)]-Serine was purchased from PerkinElmer, Inc. (Wellesley, MA, USA).
Human breast cancer cell line MDA-MB-231, from America Type Culture Collection (ATCC),
Rockville, MD, USA, was chosen as the source of serine-palmitoyl transferase (SPT) enzyme. Cells
were maintained at 5% CO2, 95% humidity at 37 ◦C in DMEM, supplemented with 10% FBS
and 1% penicillin/streptomycin solution as antibiotics. Cells were seeded in 150 mm Petri dishes
(3 × 106 cells in 24 mL) and left to grow for at least 3 days, until 80–90% confluence was reached,
before being collected for microsomal membranes fraction extraction, due to the localization of the
studied enzyme at this level.
3.2.2. Radiometric Inhibition Assay (RIA) Procedure
Microsomal membranes fraction was collected through MDA-MB-231 homogenization in a specific
extraction buffer (Hepes pH 7.4, 25 mM; EGTA pH 7.8, 5 mM; NaF 50 mM; leupeptin 10 µg/mL and
tripsin inhibitor 10 µg/mL) and centrifugation at 4070 rpm for 10 min at 4 ◦C. After Bradford protein
assay, the enzymatic assay was performed by incubating 300 µg of total proteins at 37 ◦C for 30 min
in the reacting buffer (Hepes pH 8.3, 100 mM, EDTA pH 7.4, 2.5 mM and DTT 5 mM) containing
pyridoxal-5’-phosphate 50 µM as enzymatic cofactor and L-[3H(G)]-Serine (1 mM, 2 µCi specific
activity 26 Ci/mmol), L-Serine (1 mM), and palmitoyl coenzyme A (200 µM) as substrates. Counts per
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minute (CPM) were measured with β-counter (Packard Tri-Carb Liquid Scintillation Analyzer, model
2900TR, GMI Inc., Ramsey, MI, USA) after washing the organic phase three times with bi-distilled
water, dividing the two phases (hydrophilic and organic) with various centrifugations, drying up the
samples overnight at 39 ◦C, and re-suspending them in scintillation cocktail. Results are expressed as
a percentage of enzymatic activity with respect to the control (DMSO) ± standard deviation.
3.3. HPLC-FL assay
3.3.1. Materials
D,L-erythro-sphinganine (erythro 77%; threo 23%) and 3-keto-dihydrosphingosine hydrochloride
(3-KDS) powders (>98.0% purity) were supplied from Matreya LLC® (Pleasant Gap, PA, USA). L-Serine,
pyridoxal 5’-phosphate monohydrate (PLP), and palmitoyl coenzyme A lithium salt (≥90%) Bioreagent
grade were purchased from Sigma-Aldrich (St. Louis, MI, USA). Dimethylsulphoxide (DMSO),
absolute ethanol, O-phthalaldehyde (OPA), 2-mercaptoethanol, EDTA, sodium borohydride (NaBH4),
HEPES, and ammonium hydroxide solution were purchased from Sigma-Aldrich (St. Louis, MI, USA).
HPLC grade acetonitrile (ACN), methanol (MeOH), chloroform (CHCl3), and ammonium acetate
(AcONH4) were purchased from Sigma-Aldrich (St. Louis, MI, USA). Deionised water was produced
by a Milli-Q Millipore Water System (Millipore, MA, USA). All the other reagents and materials were
of analytical grade and supplied from commercial sources. The aqueous and organic components of
the mobile phase, degassed under pressure, were mixed by the HPLC. The LC mobile phases were
filtered through 0.2 µm cellulose acetate membrane filters (Sartorius Stedim Biotech S.A., Aubagne
Cedex, France) with a solvent filtration apparatus.
Standard solutions: singular stock solutions of D,L-erythro-sphinganine and 3-KDS in MeOH
were prepared, each with a concentration of 1.0 mM, by using volumetric flasks; these were stored at
−20 ◦C. To obtain a final concentration of 100 µM, appropriate dilutions of stock standard solutions
were prepared by diluting 1 mL of each solution to 10 mL. Successively, these solutions were diluted
in glass tubes (10 mL), to reach final concentrations of 10, 1 and 0.1 µM. These were stored at −20 ◦C.
Stock solutions: borate buffer (pH 10.5; 3% p/v): 3.00 g of boric acid were dissolved in milliQ
water. NaOH was added to reach pH = 10.5. The solution was brought to volume using a 100 mL
volumetric flask. The buffer was stored at 3 ◦C. OPA (O-phthalaldehyde): 50 mg of OPA were dissolved
in 1 mL of EtOH. The solution was stored in an amber glass vial at 3 ◦C (1 month maximum). EDTA
(pH 8; 0.5 M): 1.86 g of EDTA were dissolved in milliQ water and pH is adjusted by addition of NaOH.
The solution was brought to volume in a 50 mL volumetric flask. HEPES buffer (pH 8.0; 0.5 M): 5.95 g
of HEPES was dissolved in milliQ water and pH was adjusted by addition of NaOH. The solution
was brought to volume in a 50 mL volumetric flask. Lysis buffer: 1 mL of HEPES buffer and 20 mL of
EDTA were mixed and brought to volume in a 10 mL volumetric flask. An amount of 200 mM L-Serine:
210.18 mg of L-Serine was dissolved in milliQ H2O and brought to volume in a 10 mL volumetric flask.
An amount of 5 mM PLP: 61.785 mg of PLP was dissolved in milliQ H2O and brought to volume in a
50 mL volumetric flask. Palmitoyl-CoA (lithium salt; 5 mM): 5.0 mg of palmitoyl coenzyme A lithium
salt was dissolved in 1 mL of milliQ H2O.
Freshly prepared solutions: “derivatization solution”: in 1.5 mL snap cap vial, 990 µL of borate
buffer (pH 10.5; 0.5 mM), 10 µL of OPA (50 mg/mL in ethanol), and 0.5 µL of 2-mercaptoethanol were
mixed. MeOH/EtOH/H2O (85:47.5:17.5, v/v/v) solution: in a 15 mL falcon tube, 3.40 mL of MeOH,
1.9 mL of EtOH, and 0.7 mL of milliQ H2O were mixed. MeOH/CHCl3 (2:1, v/v): in a 15 mL falcon
tube, 10 mL of MeOH, and 5 mL of CHCl3 were mixed. Sodium borohydride (NaBH4) solution: about
6 mg of sodium borohydride was dissolved in 1 mL of milliQ water. Substrates mix: to 125 µL of
L-Serine were added 20 µL of PLP, 50 µL of palmitoyl-CoA and 55 µL of milliQ H2O.
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3.3.2. HPLC-FL Assay Procedure
The HPLC system was an LC Workstation Prostar (Varian, Inc., Walnut Creek, CA, USA) consisting
of a high-pressure mixer pump (ProStar, model 230), CTO-10Avp column oven, spectrofluorometric
detector (ProStar, model 363), and a loop of 50 µL. Data were processed by a Star LC Workstation
(Varian, Inc.). Chromatographic separation assay was performed by a Luna C18 ODS2 analytical
columns (150 × 4.6 mm inner diameter, 3 µm particle size, Phenomenex, Torrance, CA, USA)
maintained at 25 ◦C. The mobile phase consisted of acetonitrile-buffer (10 mM AcONH4, adjusted
to pH 7.0 with NH4OH) (90:10, v/v) at a flow rate of 0.8 mL/min. Excitation and emission
wavelengths were set at 335 and 440 nm, respectively. The analyses were carried out in isocratic
mode. Results are expressed as a percentage of enzymatic activity with respect to the control
(vehicle) ± standard deviation.
3.4. Cell Culture and SPT Cell Lysate Preparation
Human embryonic kidney cells (HEK293) were grown in DMEM-F12 medium. Cultures were
maintained at 37 ◦C in a 5% CO2 atmosphere at 100% humidity. Cell membrane microsomes were
prepared as follows: a HEK293 cell monolayer in a 10 cm dish was washed with 5 mL of PBS and
mechanically removed through a scraper. Then, the petri dish was washed with 5 mL of PBS. The cell
suspension was collected and centrifuged for 5 min at 1200 rpm. Then, the pellet was suspended in
500 µL lysis buffer (pH 8; 50 mM HEPES and 1 mM EDTA). The cell suspension was sonicated for 15 s
at 50% power and 50% pulsation (Sonopuls HD 2070; Bandelin, Berlin, Germany) and centrifuged at
2500 rpm at 4 ◦C for 30 min. The supernatant was then centrifuged at 33,000 rpm for 40 min at 4 ◦C.
The pellet was re-suspended in the lysis buffer: protein determination was performed by colorimetric
Bradford assay, using the protein assay kit from Bio-Rad (Hercules, CA, USA). Cell lysate was diluted
to reach a concentration of ≈2 mg/mL and used to evaluated SPT activity.
3.5. Incubation and Sample Extraction Procedure
The procedure was performed in a 1.5 mL snap cap polypropylene vial. To a 180 µL aliquot of
cell lysate (≈2 mg/mL) was added 10 µL of inhibitor solution or vehicle (control sample) and 10 µL of
“substrate mix” (L-serine, PLP, palmitoyl-CoA). Samples were incubated at 37 ◦C for 1 h. Experiments
were performed in triplicate. To ensure the absence of interferences, a background analysis of each cell
lysate batch was carried out. After incubation, 50 µL of a NaBH4 aqueous solution (≈6 mg/mL) was
added to samples and left to react at RT for 5 min. Then, 100 µL of NH4OH (2 M) was added. Each
sample was vortexed for 10 s; then, 600 µL of MeOH/CHCl3 (2:1, v/v) was added and the sample
vortexed again (30 s). Once the organic and aqueous phase separation was achieved by centrifugation
(14,000 rpm, 1 min), 200 µL of the supernatant was removed and 600 µL of NH4OH (2 mM) was added.
The sample was vortexed for 30 s and centrifuged at 14,000 rpm for 1 min. An amount of 150 µL of the
organic phase was collected and evaporated under a gentle stream of nitrogen in an amber glass vial.
The residue was reconstituted with 145 µL of MeOH/EtOH/H2O (85:47.5:17.5, v/v/v) and 5 µL of
“derivatization solution” was added. Derivatization reaction was performed at 40 ◦C for 2 h. Then,
50 µL of this latter solution was injected onto the HPLC-FL. SPT initial velocity was evaluated by
performing different incubation periods (5, 30, 60, 90, 120 and 150 min) at 37 ◦C. Each incubation period
was tested in triplicate. Subsequently, the selected compounds were tested in HPLC-FL in triplicate.
3.6. Bioanalytical Method Validation
The described method was validated in terms of linearity, lower limit of detection and
quantification (LLOD and LLOQ), recovery, specificity, stability, precision, and trueness according to
international guidelines on the bioanalytical method validation. Calibration curves were obtained
by spiking the blank matrix with a known concentration of D,L-erythro-sphinganine to provide
concentrations of 0.010, 0.020, 0.050, 0.075, 0.10, 0.20, 0.40, 0.80, 1.60 and 3.20 µM. The calibration curves
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of peak area versus concentration of D,L-erythro-sphinganine were built. Least squares regression
parameters for the calibration curve were calculated, and the concentrations of the test samples
were interpolated from the regression parameters. Sample concentrations were determined by linear
regression, using the formula Y = mX + b, where Y = peak area, X = concentration of the standard,
m = the slope of the curve and b = the intercept with y-axis. Correlation coefficient for the calibration
curves was >0.99. Accuracy and within-run and between-run precision were assessed on quality
control samples (QC samples) and determined by replicate analysis using seven determinations of
different concentration levels: Low QC (100 nM), medium QC (800 nM), and high QC (1600 nM). When
unknown samples were assayed, a control and a fortified blank sample were processed simultaneously
for quality control. LLOD and LLOQ were determined as analyte concentrations giving signal-to-noise
ratios of 3 and 10, respectively. All the analyses were conducted using GraphPad InStat (GraphPad
Software, Inc., La Jolla, CA, USA).
4. Conclusions
In this work, we described the application and validation of an HPLC-FL-based method to screen
the SPT-inhibitory activity of two heterocyclic compounds reported in a patent [18] and which were
re-synthesized in our research laboratories. Different steps of method development and optimization
were pursued: in a first stage, analytical conditions were developed by evaluating the derivatization
and chromatographic condition, extraction procedure, and method validation according to EMEA
guidelines. After optimization of the analytical conditions, the assay procedure was evaluated in
relation to enzyme initial velocity. Once fully optimized, the method was applied to assess the
SPT-inhibitory activity of the above-mentioned derivatives and of the reference SPT-inhibitor myriocin.
The obtained results showed a good correlation between the reference RIA method and the HPLC-FL
method. So, the improvements introduced in the analytical procedure made this non-radiometric
method easily applicable in medicinal chemistry labs for a preliminary and rapid screening of potential
SPT-inhibitors characterized by diverse chemical structures.
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